Novartis begins Phase IIIb trial of secukinumab versus stelara to treat plaque psoriasis

Swiss drug maker Novartis has started enrolling patients in a new Phase IIIb head-to-head trial of IL-17A inhibitor secukinumab (AIN457) versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news